# Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)

> **NCT03354962** · PHASE1,PHASE2 · TERMINATED · sponsor: **Institut Claudius Regaud** · enrollment: 6 (actual)

## Conditions studied

- Melanoma

## Interventions

- **COMBINATION_PRODUCT:** Nivolumab + Ipilimumab
- **COMBINATION_PRODUCT:** Combined treatment schema

## Key facts

- **NCT ID:** NCT03354962
- **Lead sponsor:** Institut Claudius Regaud
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-15
- **Primary completion:** 2020-02-20
- **Final completion:** 2020-10-27
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Slow recruitment rate
- **Last updated:** 2020-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03354962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03354962, "Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03354962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*